SPECIAL REPORT
The following summarizes some of the key data on ofatumumab from the American Academy of Neurology annual meeting (AAN), San Diego, CA, April 5-9, 2025.
Efficacy in early MS
First-line use of ofatumumab
Long-term efficacy and safety
Safety in pregnancy
Tuesday Edition
Monday Edition
The following summarizes some of the highlights from Day 3 of the American Academy of Neurology annual meeting (AAN), San Diego, CA, April 5-9, 2025.
MS risk with head trauma
Efficacy of first-line ofatumumab in patients without highly active disease
Semaglutide may reduce MS progression
Higher MS risk with earlier menarche
Biomarker dynamics after DMT initiation
Clinical tip of the day
Wednesday Edition
Monday Edition
The following summarizes some of the highlights from Day 2 of the American Academy of Neurology annual meeting (AAN), San Diego, CA, April 5-9, 2025.
Ofatumumab long-term data
KFLC a long-term predictor of disability worsening
BAFF a potential predictor of low Ig
Tolebrutinib in SPMS
Clinical tip of the day
Wednesday Edition
Tuesday Edition
The following summarizes some of the highlights from Day 1 of the American Academy of Neurology annual meeting (AAN), San Diego, CA, April 5-9, 2025.
Spinal cord lesion count not correlated with disability in SPMS
Effect of DMTs on EBV response
Frexalimab 96-week data
Worrisome side effect of CAR-T therapy
Managing pseudobulbar affect (PBA) in MS
Clinical tip of the day